Mike Israetel

The price situation, I don't really particularly understand that criticism. What specifically is the criticism about the price?

The price situation, I don't really particularly understand that criticism. What specifically is the criticism about the price?

The price situation, I don't really particularly understand that criticism. What specifically is the criticism about the price?

Our healthcare system suffers from an insane burden of over-regulation by a humongous, humongous factor. That's definitely a problem. Part of the ways that problem presents itself is sometimes egregiously high prices for pharmaceutical medicine. But almost never are these prices actually prices people pay. These are prices charged to insurance companies.

Our healthcare system suffers from an insane burden of over-regulation by a humongous, humongous factor. That's definitely a problem. Part of the ways that problem presents itself is sometimes egregiously high prices for pharmaceutical medicine. But almost never are these prices actually prices people pay. These are prices charged to insurance companies.

Our healthcare system suffers from an insane burden of over-regulation by a humongous, humongous factor. That's definitely a problem. Part of the ways that problem presents itself is sometimes egregiously high prices for pharmaceutical medicine. But almost never are these prices actually prices people pay. These are prices charged to insurance companies.

And there's a bit of a funky thing there where you can charge an insurance company a lot more money than you can charge an individual. An individual will just be like, nah, I'm not buying that. But if you can get it approved through your insurance, they can begrudgingly approve it in some cases. And so they can pay much more money for the drug.

And there's a bit of a funky thing there where you can charge an insurance company a lot more money than you can charge an individual. An individual will just be like, nah, I'm not buying that. But if you can get it approved through your insurance, they can begrudgingly approve it in some cases. And so they can pay much more money for the drug.

And there's a bit of a funky thing there where you can charge an insurance company a lot more money than you can charge an individual. An individual will just be like, nah, I'm not buying that. But if you can get it approved through your insurance, they can begrudgingly approve it in some cases. And so they can pay much more money for the drug.

So in a properly competitive market oriented drug development environment, you have multiple drugs competing and a direct patient to drug purchasing pipeline with the approval of a doctor, of course. So if I'm actually able to buy these drugs out of pocket, And I see that terzapatide costs two times less than semaglutide. I'm buying terzapatide for sure.

So in a properly competitive market oriented drug development environment, you have multiple drugs competing and a direct patient to drug purchasing pipeline with the approval of a doctor, of course. So if I'm actually able to buy these drugs out of pocket, And I see that terzapatide costs two times less than semaglutide. I'm buying terzapatide for sure.

So in a properly competitive market oriented drug development environment, you have multiple drugs competing and a direct patient to drug purchasing pipeline with the approval of a doctor, of course. So if I'm actually able to buy these drugs out of pocket, And I see that terzapatide costs two times less than semaglutide. I'm buying terzapatide for sure.

But if I really want semaglutide, I'll pay double or whatever. The way this works in every single market ever studied is that eventually prices trend to very, very low levels because of the fierce competition of companies who make different drugs. There's also a bunch of drugs in development. In the next few years, we'll have a bunch more released.

But if I really want semaglutide, I'll pay double or whatever. The way this works in every single market ever studied is that eventually prices trend to very, very low levels because of the fierce competition of companies who make different drugs. There's also a bunch of drugs in development. In the next few years, we'll have a bunch more released.

But if I really want semaglutide, I'll pay double or whatever. The way this works in every single market ever studied is that eventually prices trend to very, very low levels because of the fierce competition of companies who make different drugs. There's also a bunch of drugs in development. In the next few years, we'll have a bunch more released.

And then Ozempic, for example, will be like four years outdated and you will almost certainly find it super, super cheap. Am I for making drugs substantially cheaper via deregulation? By God, I couldn't say any more about that. Like, absolutely. But is it some like specifically nefarious thing between Denmark and the United States? I'm not so sure that that's the case. I would be curious.

And then Ozempic, for example, will be like four years outdated and you will almost certainly find it super, super cheap. Am I for making drugs substantially cheaper via deregulation? By God, I couldn't say any more about that. Like, absolutely. But is it some like specifically nefarious thing between Denmark and the United States? I'm not so sure that that's the case. I would be curious.

And then Ozempic, for example, will be like four years outdated and you will almost certainly find it super, super cheap. Am I for making drugs substantially cheaper via deregulation? By God, I couldn't say any more about that. Like, absolutely. But is it some like specifically nefarious thing between Denmark and the United States? I'm not so sure that that's the case. I would be curious.

The ideal amount of money supplement or drug companies would charge you is infinity. And the ideal amount of drug they would ship you is zero. Your ideal is that they charge you nothing and give you all the drugs you want. The market finds an equilibrium somewhere between those two points. So the price issue is a technical economic discussion.

The ideal amount of money supplement or drug companies would charge you is infinity. And the ideal amount of drug they would ship you is zero. Your ideal is that they charge you nothing and give you all the drugs you want. The market finds an equilibrium somewhere between those two points. So the price issue is a technical economic discussion.